The role of osteopontin: A shared pathway in the pathogenesis of multiple sclerosis and osteoporosis?

Osteopontin (OPN) was suggested to have a role in the pathophysiology of MS and in bone metabolism. However, we formerly reported increased presence of osteoporosis in MS patients independent of corticosteroid treatment, there is only limited information about the mechanism of bone loss. In this study, we investigated the role of OPN on bone mineral density in MS patients. Thirty-three relapsing–remitting (RR), 12 secondary progressive (SP), and 5 primary progressive (PP) MS patients and 30 healthy controls were prospectively enrolled. Students' t test, chi-square test, and Pearson correlations were used. The mean OPN level was 155.4 ± 81.8 ng/ml in controls, and 15.9 ± 36.2 ng/ml in MS patients (p < 0.001).No statistical difference was observed among RR, SP and PPMS patients (p = 0.162). No relationship was found between OPN levels and age at onset of disease (p = 0.830), gender (p = 0.785), MS subtypes (p = 0.330), disease duration (p = 0.744), or EDSS scores (p = 0.633).About 34% of MS patients versus 10.3% of controls had osteoporosis (p = 0.017).Osteopontin levels showed no significant correlation with osteoporosis in controls, but were lower in MS patients with osteoporosis in femur neck (r = 0.85, p = 0.010).The cumulative dose of corticosteroid treatment did not correlate with OPN levels (p = 0.285).In conclusion, our results suggest that OPN may have a role as a shared cytokine in pathogenesis of MS and osteoporosis.